Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.48 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138013 | 0.88 | MME (0.58) | MMELMNAPOLBGPR88GRM7 | |
| SCHEMBL16312241 | 0.86 | MME (0.61) | MMELMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL20725227 | 0.86 | MME (0.61) | MMELMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL7886625 | 0.83 | MME (0.58) | MMELMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL7960070 | 0.82 | GPR88 (0.59) | MMEGAASMN1; SMN2GPR88PTGS2 | |
| SCHEMBL24571671 | 0.81 | GPR88 (0.55) | MMELMNAPOLBGPR88GRM7 | |
| SCHEMBL4156225 | 0.81 | MME (0.64) | MMELMNASMN1; SMN2POLBGPR88 | |
| SCHEMBL24571811 | 0.81 | GPR88 (0.55) | MMELMNAPOLBGPR88GRM7 | |
| SCHEMBL24045909 | 0.81 | CXCR1 (0.64) | LMNAGAASMN1; SMN2PTGS2 | |
| SCHEMBL24045925 | 0.81 | CXCR1 (0.64) | LMNAGAASMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS | 2005-07-21 | — | — | US | disclosed |
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | BACE1, APP, BACE2 | MME 18/4885LMNA 2047/4885GAA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.